Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.07 (-8.12%)
Close on Nov 12, 2026Market cap $285.72MP/E –Yield 0.00%
Allogene Therapeutics cash
Cash and short-term investments held at the end of each period.
Allogene Therapeutics's cash was $388.90M at Sep 30, 2026. For fiscal 2025 it was $258.30M, down 30.8% from the year before. The highest annual figure on record is $1.00B in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $258.30M | -30.8% |
| FY2024 | Dec 31, 2024 | $373.10M | -16.8% |
| FY2023 | Dec 31, 2023 | $448.70M | -22.2% |
| FY2022 | Dec 31, 2022 | $576.50M | -28.8% |
| FY2021 | Dec 31, 2021 | $809.50M | -19.1% |
| FY2020 | Dec 31, 2020 | $1.00B | +69.8% |
| FY2019 | Dec 31, 2019 | $588.90M | -18.4% |
| FY2018 | Dec 31, 2018 | $721.40M | – |
| FY2017 | Dec 31, 2017 | $0 | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $388.90M | +40.3% |
| Q2 FY2026 | Jun 30, 2026 | $423.60M | +40.0% |
| Q1 FY2026 | Mar 31, 2026 | $266.90M | -20.4% |
| Q4 FY2025 | Dec 31, 2025 | $258.30M | -30.8% |
| Q3 FY2025 | Sep 30, 2025 | $277.10M | -31.3% |
| Q2 FY2025 | Jun 30, 2025 | $302.60M | -31.9% |
| Q1 FY2025 | Mar 31, 2025 | $335.50M | -15.6% |
| Q4 FY2024 | Dec 31, 2024 | $373.10M | -16.8% |
| Q3 FY2024 | Sep 30, 2024 | $403.40M | -18.9% |
| Q2 FY2024 | Jun 30, 2024 | $444.60M | -18.3% |
| Q1 FY2024 | Mar 31, 2024 | $397.30M | -22.7% |
| Q4 FY2023 | Dec 31, 2023 | $448.70M | -22.2% |
| Q3 FY2023 | Sep 30, 2023 | $497.70M | -21.9% |
| Q2 FY2023 | Jun 30, 2023 | $544.50M | -20.6% |
| Q1 FY2023 | Mar 31, 2023 | $514.00M | -29.9% |
| Q4 FY2022 | Dec 31, 2022 | $576.50M | -28.8% |
| Q3 FY2022 | Sep 30, 2022 | $637.30M | -26.0% |
| Q2 FY2022 | Jun 30, 2022 | $686.10M | -24.9% |
| Q1 FY2022 | Mar 31, 2022 | $733.10M | -24.0% |
| Q4 FY2021 | Dec 31, 2021 | $809.50M | -19.1% |
| Q3 FY2021 | Sep 30, 2021 | $861.70M | -13.8% |
| Q2 FY2021 | Jun 30, 2021 | $913.20M | -17.0% |
| Q1 FY2021 | Mar 31, 2021 | $964.20M | +74.4% |
| Q4 FY2020 | Dec 31, 2020 | $1.00B | +69.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.00B | +66.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.10B | +69.2% |
| Q1 FY2020 | Mar 31, 2020 | $553.00M | -18.8% |
| Q4 FY2019 | Dec 31, 2019 | $588.90M | -18.4% |
| Q3 FY2019 | Sep 30, 2019 | $601.90M | +51.1% |
| Q2 FY2019 | Jun 30, 2019 | $650.20M | +351.8% |
| Q1 FY2019 | Mar 31, 2019 | $680.70M | +13613900.0% |
| Q4 FY2018 | Dec 31, 2018 | $721.40M | – |
| Q3 FY2018 | Sep 30, 2018 | $398.30M | – |
| Q2 FY2018 | Jun 30, 2018 | $143.93M | – |
| Q1 FY2018 | Mar 31, 2018 | $5.00K | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
See a number that looks wrong?